Context. Medium to high dose glucocorticoids represents the treatment of choice for inducing remission in IgG4-related type 1 autoimmune pancreatitis (IgGRD-AIP). However, in clinical settings where long-term corticosteroids treatment is contraindicated (e.g. diabetes and osteoporosis) alternative equally effective drugs would be recommendable. Objective. To assess the efficacy of methotrexate (MTX) as induction of remission therapy in selected cases of IgG4RD-AIP complicated by clinical scenarios that might advise against the use of corticosteroids. Methods. Three patients with active untreated IgG4RD-AIP were started on oral or subcutaneous MTX. Efficacy of MTX in inducing remission was assessed at 6 months by 18F-FDG PET/CT scan, IgG4-RD Responder Index (RI), serum IgG4 levels, and circulating plasmablasts (PBs). Results. All patients presented with exocrine pancreatic insufficiency; none had obstructive jaundice; all had overt diabetes. Baseline and post-treatment characteristics are presented in Table 1. After 6 months of MTX all patients were on complete remission with normal PBs and markedly improved PET findings. Conclusions. In some cases of IgG4RD-AIP with mild manifestations but with contraindications to glucocorticoids, MTX might represent a promising alternative strategy for inducing disease remission.

Methotrexate as induction of remission the-rapy for IgG4-Related type 1 Autoimmune Pancreatitis

DELLA TORRE E;Marco Lanzillotta;Paolo Arcidiacono;Stefano Crippa;Stefano Partelli;Massimo Falconi;Lorenzo Dagna
2017-01-01

Abstract

Context. Medium to high dose glucocorticoids represents the treatment of choice for inducing remission in IgG4-related type 1 autoimmune pancreatitis (IgGRD-AIP). However, in clinical settings where long-term corticosteroids treatment is contraindicated (e.g. diabetes and osteoporosis) alternative equally effective drugs would be recommendable. Objective. To assess the efficacy of methotrexate (MTX) as induction of remission therapy in selected cases of IgG4RD-AIP complicated by clinical scenarios that might advise against the use of corticosteroids. Methods. Three patients with active untreated IgG4RD-AIP were started on oral or subcutaneous MTX. Efficacy of MTX in inducing remission was assessed at 6 months by 18F-FDG PET/CT scan, IgG4-RD Responder Index (RI), serum IgG4 levels, and circulating plasmablasts (PBs). Results. All patients presented with exocrine pancreatic insufficiency; none had obstructive jaundice; all had overt diabetes. Baseline and post-treatment characteristics are presented in Table 1. After 6 months of MTX all patients were on complete remission with normal PBs and markedly improved PET findings. Conclusions. In some cases of IgG4RD-AIP with mild manifestations but with contraindications to glucocorticoids, MTX might represent a promising alternative strategy for inducing disease remission.
2017
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/20.500.11768/118590
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus ND
  • ???jsp.display-item.citation.isi??? ND
social impact